Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bastian, P. J.
Right arrow Articles by von Ruecker, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bastian, P. J.
Right arrow Articles by von Ruecker, A.
Clinical Cancer Research Vol. 11, 4097-4106, June 1, 2005
© 2005 American Association for Cancer Research

Imaging, Diagnosis, Prognosis

Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci

Patrick J. Bastian1, Jörg Ellinger2, Axel Wellmann2, Nicolas Wernert2, Lukas C. Heukamp2, Stefan C. Müller1 and Alexander von Ruecker2

Authors' Affiliations: 1 Klinik und Poliklinik für Urologie and 2 Institut für Pathologie, Universitätsklinikum Bonn, Rheinische Friedrich-Wilhelms Universität Bonn, Bonn, Germany

Requests for reprints: Patrick J. Bastian, Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Sigmund Freud Straße 25, 53105 Bonn, Germany. Phone: 49-228-2875109; Fax: 49-228-2874285; E-mail: patrick.bastian{at}ukb.uni-bonn.de.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Our study was designed to evaluate promoter CpG island hypermethylation in the diagnosis and prognosis of prostate cancer.

Experimental Design: Primary prostate cancers from 53 patients, pelvic lymph nodes, noncancerous prostate tissues, and prostate cell lines were analyzed. Real-time methylation-specific PCR was used to identify CpG island hypermethylation at five promising gene loci (i.e., GSTP1, APC, PTGS2, MDR1, and RASSF1a).

Results: At three gene loci (GSTP1, APC, and PTGS1) and CpG island, hypermethylation was highly prevalent in prostate cancers (71-91%), and analysis of receiver operator curves showed that hypermethylation at these three gene loci can distinguish between prostate cancer and noncancerous prostatic tissue (i.e., benign hyperplasia) with a sensitivity of 71.1% to 96.2% and a specificity of 92.9% to 100%. Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis. Methylation characteristics in prostate cancer metastases (i.e., pelvic lymph nodes) were comparable to the respective primary cancer. Statistical analysis showed no correlation between the methylation status of a single gene locus and clinicopathologic variables (e.g., preoperative prostate specific antigen levels, Gleason score, capsular penetration, involvement of seminal vesicle, and age). In contrast, the methylation of two (GSTP1/APC; GSTP1/PTGS2) or three (GSTP1/APC/PTGS2) gene loci correlated with prognostic indicators (i.e., pathologic stage, extraprostatic extension, and Gleason score, but not with prostate specific antigen levels).

Conclusions: Our data suggest that the evaluation of DNA hypermethylation at three gene loci (i.e., GSTP1, APC, and PTGS2) is of diagnostic and prognostic value in prostate cancer.

Key Words: CpG island hypermethylation • Prostate cancer

Prostate cancer is the most common cancer in men and the second leading cause of cancer-related deaths in the United States and Western Europe. Since the beginning of the prostate specific antigen (PSA) testing era in the late 1980s, there has been a significant increase in the diagnosis of men with nonpalpable prostate cancer (1, 2). Autopsy studies and the recent Prostate Cancer Prevention Trial have revealed a higher prevalence of prostatic cancer than anticipated by PSA screening alone (3–5). The lifetime risk of developing prostate cancer in the United States is 1 in 6, whereas the lifetime risk of death due to metastatic prostate cancer is 1 in 30 (6). It is estimated that 230,000 to 240,000 new cases will be diagnosed in 2004/2005 and about 30,000 men will die of the disease in the United States at the same time (6). In Western European countries without prostate cancer screening, a somewhat lower prevalence is found, with age-standardized incidence rates of 54.92 per 100,000 (United States: 104.33 per 100,000; ref. 7).

PSA screening, regardless of the threshold value, has certain well-documented limitations with regards to sensitivity and specificity for the detection of prostate cancer (8). Therefore ultrasound-guided prostate biopsy is still the gold standard method for diagnosing prostate cancer. The precise biopsy strategy in terms of the number of samples and the sampled area, however, remains controversial (9, 10). Moreover, nondiagnostic but clinically suspicious lesions, such as a small focus of atypical glands or high-grade prostatic intraepithelial neoplasia, necessitate further evaluation in the absence of obvious cancer in the specimen (11).

Molecular studies have revealed important information about prostate cancer development and progression (8). Furthermore, multiple immunohistochemistry tools to aid the diagnosis of prostate cancer have been developed. As of yet, none of these procedures, alone or in conjunction, have been able to definitively diagnose prostate cancer (12–16). Presently, the emergence of new molecular tests may improve identification of early neoplastic alterations in prostatic cells, but only a few have been adequately validated for clinical use (8, 17, 18).

Epigenetic alterations (i.e., aberrant DNA methylation patterns, generalized hypomethylation, and regional CpG island hypermethylation) are characteristics of tumor cells (19). The earliest and most common somatic genome alteration during prostate cancer development seems to be CpG island hypermethylation in the regulatory region of the {pi}-class glutathione S-transferase (GSTP1) gene (>90%; refs. 8, 20). The detection of GSTP1 CpG island hypermethylation in bodily fluids like urine or serum even reaches sensitivities up to 76% (21, 22). However, the use of a single gene locus has several drawbacks. First, the maximum sensitivity can only be as high as the frequency of hypermethylation at a specific CpG locus. Second, noncancerous tissues can in some cases harbor CpG island hypermethylation at the same gene locus. Third, methylation of a single gene locus may occur in other cancers and thus be misleading in prostate cancer (23). Furthermore, it has been shown that the number of hypermethylated genes increases as prostate cancer progresses; thus, the investigation of several genes may provide additional diagnostic information (24, 25).

To establish a small set of reliable diagnostic investigations in prostate cancer, we quantitatively assessed the methylation status of CpG islands in the regulatory regions of GSTP1 and four other genes we thought promising. Reports in the literature have shown that these genes are either silenced or activated by hypermethylation/hypomethylation mechanisms and/or play important roles in many human neoplasms:

  1. APC (adenomatosis polyposis coli): a well-characterized tumor suppressor involved in down-regulating WNT/ß-catenin signaling and central to development and the mature organism. Initially identified in colorectal cancer, APC is inactivated in various malignancies including prostate cancer by genetic and epigenetic mechanisms (23, 26–29).
  2. PTGS2 [prostaglandin-endoperoxide synthase 2 or cyclooxygenase 2 (COX-2)]: involved in the regulation of inflammation (e.g., T-helper-2 response) and mitogenesis/carcinogenesis, presumably inactivated in apoptosis. It is presumably up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma, by genetic/epigenetic alterations (30).
  3. MDR1 (multidrug resistance 1): encodes the P-glycoprotein and is a member of the ATP-binding cassette transporter gene superfamily that regulates the trafficking of drugs, peptides, xenobiotics, and ions across cell membranes. Its expression correlates with resistance to hormone therapy and is thought to be important in the progression of primarily hormone-sensitive malignancies like prostate cancer. Activation of MDR1 occurs rapidly in response to varied cellular stresses, and epigenetic hypomethylation may hereby play a role (28, 31–35).
  4. RASSF1a (Ras association domain family 1 isoform A): a tumor suppressor that interacts with Cdc20, an activator of the anaphase-promoting complex, resulting in the inhibition of activity of complexes and the prevention of mitotic progression. It conserves cyclins A and B, and its expression correlates with proapoptotic activity. Epigenetic inactivation of RASSF1a is frequently observed in a number of solid tumors and epithelial cancers including prostate cancer (24, 28, 29, 36–43).

Our data show that combining the CpG island methylation status of three of these genes (i.e., GSTP1, APC, and PTGS2) provides the clinician with valuable diagnostic and prognostic information. The significance of the hypermethylation of RASSF1a and MDR1 that was observed in benign prostate hyperplasia (BPH) as well as prostate cancer is discussed.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Patients and sample collection. A total of 53 consecutive patients with prostate cancer and 14 consecutive patients with BPH were recruited into this study. All tissue samples were obtained during urological standard procedures (radical or open prostatectomy, radical cysto-prostatectomy) done at the Department of Urology, University of Bonn, Germany, between 2000 and 2003. All patients had given written informed consent for the collection of tissue and further analysis according to the institutional ethical guidelines before surgery. Pelvic lymph nodes were obtained during radical prostatectomy for clinically localized prostate cancer in every patient. All cancerous and noncancerous samples were meticulously surveyed by pathologists and microdissected to ensure a high grade of prostatic epithelia purity (>70% cancer cells by microscopic examination). Clinical information is listed in Table 1. Follow-up information was available for 23 of the 53 patients (3-38 months; median, 21 months). Biochemical recurrence (i.e., PSA > 0.2 ng/mL) was observed in two patients (mean onset, 24 months).


View this table:
[in this window]
[in a new window]
  		Table 1. Clinical information of patients

 
Three prostate cancer cell lines (LNCaP, DU-145, and PC-3) and one BPH cell line (BPH-1) were studied. The cell lines were obtained from the "Deutsche Sammlung für Mikroorganismen und Zellkultur," Braunschweig, Germany, and cultured according to the protocol of the vendor (http://www.dsmz.de). Briefly, cell lines were grown in RPMI 1640 containing 10% fetal bovine serum and 35 units/mL Pen/Strep (all ingredients from PAA Laboratories, Coelbe, Germany). Additionally, BPH-1 medium contained 1% insulin, transferrin, and selenium supplement and 0.1% testosterone (Sigma, Seelze, Germany). Cell lines were grown in 5% CO2/95% air at 37°C.

DNA isolation. The archival, formalin-fixed, paraffin-embedded tissues were cut in 20 µm serial sections. At the beginning and end of each section, a 7.5-µm-thick cut was taken for H&E staining. The area of prostate cancer or BPH was marked by an experienced pathologist and subsequently microdissected. After deparaffinization using xylol and ethanol, we isolated genomic DNA using the Qiagen DNA Mini Kit (Qiagen GmbH, Hilden, Germany). DNA isolation from pelvic lymph nodes revealed sufficient yield for further analysis in only 15 of 53 patients. Only 3 of these 15 lymph nodes had metastatic involvement. Additionally, cell lines and healthy volunteers' WBC DNA were isolated using the Qiagen DNA Mini kit. Universal methylated DNA was prepared by treatment of WBC-DNA with SssI CpG methylase (New England Biolabs, Frankfurt, Germany).

Sodium bisulfite treatment. Sodium-bisulfite modification was done according to Grunau et al. (44). In short, four aliquots of 2 µg DNA and 2 µg tRNA carrier were dissolved in 100 µL distilled water and denatured in a final concentration of 0.3 mol/L NaOH for 20 minutes at 37°C. Afterwards, 520 µL of a 3.87 mol/L sodium bisulfite solution (pH 5) containing hydroquinone at a final concentration of 10 mmol/L were added and incubated at 55°C for 18 hours in the dark. The modified DNA was desalted with QIAEx II (Qiagen) and the four aliquots were dissolved in 100 µL of 1 mmol/L Tris-HCl (pH 8). Final desulfonation was done (0.3 mol/L NaOH for 20 minutes at 37°C), followed by neutralization with 47 µL of 10 mol/L ammonium acetate and addition of 1 µg tRNA. Finally, after overnight ethanol precipitation, these were washed in 70% ethanol and the DNA was resuspended in 140 µL of 1 mmol/L Tris-HCl (pH 8). Modified DNA was stored for less than 6 weeks. All reagents not otherwise specified were from Sigma-Aldrich (Seelze, Germany).

Real-time methylation-specific PCR. We did real-time methylation-specific PCR amplification of the promoter/regulatory regions of GSTP1, APC, PTGS2, MDR1, and RASSF1a. MYOD1 served as internal reference. The primer sequences to amplify bisulfite-converted CpG islands are listed in Table 2. Primers sequences were obtained from previously published data [MYOD1 (45), RASSF1a (46), or self-designed (GSTP1, APC, PTGS2, and MDR1) with MethPrimer (http://www.ucsf.edu/urogene/methprimer; ref. 47)]. All PCR experiments were carried out in a volume of 10 µL with 384-well plates and an Applied Biosystems 7900HT Sequence Detector (Perkin-Elmer, Foster City, CA). The fluorescence signal of the quantitative methylation-specific PCR was generated by SYBR Green I, a dye included in any double-stranded DNA during PCR amplification (SYBR Green PCR Master Mix, Applied Biosystems, Foster City, CA).


View this table:
[in this window]
[in a new window]
  		Table 2. Primers of gene regulatory regions used in hypermethylation studies

 
Samples (2.7 µL bisulfite-treated DNA) were run in triplicate containing 5 µL SYBR Green Master Mix (Applied Biosystems) and 5.5 pmol of each forward and reverse primer. Every PCR experiment included serial dilutions of a positive control for construction of the calibration curve, a positive and a negative DNA sample, and water blanks. PCR amplification was done by means of the following procedure: 95°C for 15 minutes, followed by 40 cycles at 95°C for 30 seconds, 56°C for 20 seconds, and 72°C for 30 seconds, followed by a final 10-minute extension step at 72°C. A subsequent dissociation curve analysis checked the specificity of products. The same reaction conditions were applied to all six genes.

Relative levels of methylated DNA in each sample were calculated and described as the normalized index of methylation (NIM), as suggested by Yegnasubramanian et al. (28). The NIM defines the ratio of the normalized amount of methylated templates at the promoter to the amount of converted MYOD1 templates in any given sample and serves as an index of the percentage of bisulfite-converted input copies of DNA that are fully methylated at the primer site (28). The NIM scale from white (no methylation detected) to black (>99% of input DNA methylated) was designed with Microsoft Visual Basic (Microsoft Corporation, Seattle, WA).

Statistical analysis. Differences in the NIM between benign and cancerous tissue were tested by means of the Mann-Whitney test. Correlations between the NIM, on one hand, and between age, preoperative PSA, and Gleason score, on the other hand, were determined by Spearman's correlation coefficient. The relationship between various gene combinations and clinicopathologic variables was examined by {chi}2 or Fisher's exact test, as indicated. All tests were two sided. Statistical analysis was done with SPSS software (SPSS, Inc., Chicago, IL). The optimal threshold value that distinguishes cancer and noncancerous tissue was calculated via receiver operator curve analysis. Using the threshold value, we determined the specificity, sensitivity, positive predictive value, and negative predictive value for each gene and for multiple combinations.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Gene hypermethylation in prostate cell lines and noncancerous prostatic tissue. Figure 1A shows that the five gene loci (CpG islands) we studied are regularly hypermethylated in prostate cancer cell lines (i.e., DU-145, LNCaP, and PC-3). In the prostate hyperplasia cell line, BPH-1, CpG island hypermethylation was only observed at the RASSF1a. Figure 1B and Table 3 show that CpG island hypermethylation in BPH also occurs rather frequently at the MDR1 and RASSF1a gene loci, whereas GSTP1, APC, and PTGS2 are rarely hypermethylated.



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 1. Gene hypermethylation (expressed as NIM) at five gene loci (CpG-islands) in prostate cell lines and tissues. Methylation studies were done using real-time methylation-specific PCR as described in Materials and Methods. A, prostate cancer cell lines (LNCaP, DU-145, and PC-3) and benign prostatic hyperplasia cell line (BPH-1). B, tissue samples from various benign prostatic hyperplasias as specified in the graph. The NIM was scaled between white (no methylation) and black (>99% of input DNA was methylated).

 

View this table:
[in this window]
[in a new window]
  		Table 3. Frequencies of methylation at various gene loci (%)

 
Gene hypermethylation in clinically localized prostate cancers. Figure 2 and Table 3 show the CpG island hypermethylation status in 53 different prostate cancer tissue specimens. In all cases, sufficient amounts of DNA were extracted and thus no uninformative cases had to be taken out of the analysis. A large degree of CpG island hypermethylation was detected in all five gene loci and all tissue samples. CpG island hypermethylation was significantly different in prostate cancer and BPH, except in the case of the MDR1 locus where no distinct difference in methylation frequency was observed (Table 3).



View larger version (53K):
[in this window]
[in a new window]
  		Fig. 2. Gene hypermethylation (expressed as NIM) at five gene loci (CpG islands) in prostate cancer tissues specified in the graph and arranged according to pT stage and Gleason score. See Fig. 1 for further details.

 
Gene hypermethylation in lymph nodes of clinically localized prostate cancer. Lymph nodes with extractable/intact DNA were available from only 15 patients with prostate cancer (see Fig. 3). Histopathologic examinations revealed metastatic disease in the lymph nodes of only three of these patients. Of the five gene loci we studied, distinct CpG island hypermethylation was observed in the lymph nodes of only two of these patients. In these cases, the methylated CpG islands were similar, but the methylation index (NIM) of these loci was only vaguely related to the findings in the primary tumor (Fig. 3). On the other hand, no noteworthy hypermethylation of gene loci was observed in lymph nodes that showed no histopathologic involvement. A recent report shows that the frequency and quality (fingerprint) of CpG island hypermethylation in the metastases of prostate cancer may be similar to that in the primary tumor (28). Our small number of lymph node samples with metastasis prohibits any weighty statistical conclusions.



View larger version (56K):
[in this window]
[in a new window]
  		Fig. 3. Gene hypermethylation (expressed as NIM) at five gene loci (CpG islands) in tissues from various pelvic lymph nodes (LN) and the corresponding primary prostate cancer as specified in the graph. See Fig. 1 for further details.

 
Sensitivity and specificity of gene hypermethylation in the diagnosis of prostate cancer. To assess the usefulness of gene hypermethylation so as to discriminate between noncancerous and cancerous tissues, the sensitivity, specificity, as well as the positive and negative predictive values of hypermethylation were determined via receiver operator curve analysis Fig. 4; Table 4). This procedure revealed that hypermethylation at GSTP1, APC, and PTGS2 gene loci was the most powerful means to distinguish between cancerous and noncancerous prostatic tissue. Each gene locus had a sensitivity of >71%, a specificity >92%, and an area under the curve of >0.89. Furthermore, combining the last mentioned genes resulted in even more diagnostic power. For example, hypermethylation at GSTP1 in combination with hypermethylation at PTGS2 yields a diagnostic sensitivity of 96.2%, maintaining a specificity of 100%.



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 4. Optimal sensitivity and specificity determination for the three hypermethylated gene loci (CpG islands) in primary prostate cancer that were most promising in diagnosis. Left, receiver operator curve analysis was used to determine the methylation (NIM) threshold that yields the optimal sensitivity and specificity for each of the three hypermethylated gene loci. Right, histograms of the NIM of all prostate cancers and benign specimens are shown for each gene locus. The threshold NIM, the optimal sensitivity and specificity, and the area under the receiver operator curve (AUC) are shown for each gene locus.

 

View this table:
[in this window]
[in a new window]
  		Table 4. Diagnostic information on various hypermethylated gene loci, single and in combination

 
Correlation of hypermethylation and clinicopathologic variables. With the help of the {chi}2 and Fisher's exact test, correlation between the hypermethylation of gene loci and various previously established, clinicopathologic variables was evaluated (i.e., preoperative serum PSA level, pathologic stage of surgical specimen, organ-confined tumor, seminal vesicle involvement, pelvic lymph node involvement, pathologic Gleason score, surgical margin status, and patient age; cf. Table 5; refs. 48, 49). Hypermethylation of a single gene did not correlate with any of the examined clinicopathologic variables to a statistically significant extent. On the other hand, the simultaneous or alternative hypermethylation of two and three genes (see Table 5) significantly correlated with the pathologic stage, extraprostatic extension of the tumor, and the Gleason score. For instance, the simultaneous hypermethylation at GSTP1 and APC correlated with the pathologic stage (P = 0.049), whereas the alternative hypermethylation at GSTP1 or APC correlated with the Gleason score (P = 0.017). Furthermore, the simultaneous hypermethylation of GSTP1 and PTGS2 correlated with extraprostatic extension (P = 0.036), and the simultaneous hypermethylation of GSTP1, PTGS2, and APC correlated with the pathologic stage (P = 0.35) and extraprostatic extension (P = 0.046). Interesting but not significant was our finding that higher pathologic staging was usually accompanied by a higher gene methylation index (i.e., NIM; cf. Figs. 2 and 3).


View this table:
[in this window]
[in a new window]
  		Table 5. Correlation of clinicopathologic variables and the hypermethylation of gene loci

 
Biochemical recurrence after radical prostatectomy (PSA > 0.2 ng/mL) was seen in 2 of 23 patients with follow-up examinations (PCA-01 and PCA-20; see Fig. 2). The Gleason score was 6 and 8, respectively. Neither of these two patients had histologic infiltration of the pelvic lymph nodes. Unfortunately, no lymph node material was available to reassess DNA hypermethylation. Others have suggested (28) that a higher than median/mean methylation index (NIM) at the PTGS2 gene locus predicts recurrence. Our small data set does not underline this finding.


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
We quantitatively assessed CpG island methylation in the regulatory regions of five genes (i.e., GSTP1, APC, PTGS2, MDR1, and RASSF1a) that were likely to be silenced or activated by epigenetic alterations in prostate cancer. During the late course of our study, Yegnasubramanian et al. (28) published an article showing that our choice of genes was indeed correct and coincided with their findings that these genes are all frequently hypermethylated in prostate cancer. Technically, the main goal of our study was to show that a small set of gene loci is sufficient for a reliable diagnosis of prostate cancer.

Earlier studies with archival, formalin-fixed, paraffin-embedded tissues that were used exclusively in our project showed that the average DNA template length present in these tissues is on the order of 300 to 400 bp. A PCR product length less than 160 bp is adequate for applying methylation-specific PCR technology.3 Microdissection methods ensured a high grade of prostatic epithelia purity. Therefore, our results should not be subject to large amounts of disturbing (i.e., stromal) cells. Additionally, by using the NIM as reported by Yegnasubramanian et al. (28), we were able to approximate the fraction of DNA methylation at a given gene locus for each and every tissue sample. To our knowledge, we are the first group to use the fluorescent DNA-binding dye SYBR green in real-time methylation-specific PCR hypermethylation studies. For our purposes, SYBR green proved more sensitive in detecting hypermethylation than other techniques (i.e., quantitative real-time methylation-specific PCR using a Taqman probe; data not shown). The group of Jeronimo et al. (50) showed that conventional methylation-specific PCR is also more sensitive compared with a Taqman based real-time methylation-specific PCR assay.

Our results show and confirm that hypermethylation occurs at the chosen GSTP1, APC, PTGS2, MDR1, and RASSF1a gene loci. In the case of GSTP1 and APC, we expected and found a high rate of gene silencing by epigenetic hypermethylation in prostate cancer and practically no methylation in BPH or control tissue. In contrast, we initially expected the MDR1 gene loci to be activated and therefore hypomethylated in prostate cancer because its expression correlates with resistance to hormone sensitivity and is thought to be important in the progression of primarily hormone/androgen-sensitive malignancies like prostate cancer (31, 34, 35). Surprisingly, we found that the MDR1 locus is hypermethylated in prostate cancer and BPH. These findings confirm the results of Yegnasubramanian et al. (28) who also observed hypermethylation at the MDR1 gene loci in prostate cancer and the report of Kawai et al. (51) who showed by immunohistochemical staining that the expression of a P-glycoprotein isoform is lower in prostate cancer than in normal prostate tissues. Our finding that MDR1 is highly methylated in BPH has not been reported before and may represent early carcinogenesis or clinically relevant benign hyperplasia. The rationale behind the hypermethylation/silencing of the MDR1 gene in BPH as well as in prostate cancer awaits clarification. Possibly, a yet unidentified member of the ATP-binding cassette transporter gene superfamily is stress induced in BPH and prostate cancer, thus shutting down the expression of P-glycoprotein (32).

PTGS2 encodes COX-2 and its overexpression is associated with proinflammatory actions and the progression of various malignancies, including prostate cancer. Reports also show that COX-2 inhibitors exert antiproliferative and proapoptotic actions in prostate cancer cell lines (30). Seemingly contrary to these findings, other reports show that COX-2 may not be expressed or is down-regulated in prostate carcinoma (28, 32). Our findings support the latter reports (i.e., that the PTGS2 gene is silenced in prostate cancer by epigenetic hypermethylation). The pathophysiologic/biochemical significance of the hypermethylation of PTGS2 in prostate cancer remains as yet unclear. However, these findings do suggest that the beneficial action of COX-2 inhibitors observed in prostate cancer is not due to COX-2 enzyme inhibition.

As mentioned before, the epigenetic silencing of the tumor suppressor RASSF1a in prostate cancer has been observed by others (24, 28, 29, 36–43). Song et al. recently showed that RASSF1a contributes to the spatiotemporal regulation of mitosis through a new mechanism. By interacting with Cdc20, the RASSF1a protein inhibits the anaphase-promoting complex and prevents the degradation of cyclins A and B until the spindle checkpoint becomes fully operational (42). Exactly how RASSF1a affects mitotic progression is not known. Our results show that RASSF1a is not only silenced in prostate cancer but also partially in BPH, as well as in the respective cell lines. It has been suggested by others that the detection of epigenetic silencing of RASSF1a in BPH represents early carcinogenesis (37). However, in view of the mentioned reports, RASSF1a can act as a guardian of mitosis (42); therefore, the appearance of hypermethylation at the RASSF1a gene locus may also be a sign of clinically relevant but still benign hyperplasia.

Briefly, hypermethylation at the GSTP1, APC, and PTGS2 gene loci was significantly different in prostate cancer than in BPH and could reliably distinguish between cancerous and noncancerous tissue, whereas hypermethylation at MDR1 and RASSF1a could not. On the other hand, hypermethylation at the latter two gene loci may turn out to be useful as an early sign of carcinogenesis. In a work that was published after we had finished our investigations, the group of Tokumaru et al. (52) showed that another combination of four hypermethylated gene loci (i.e., TIG1, APC, RARß2, and GSTP1) can also detect prostate cancer with a very high sensitivity and specificity in fresh-frozen sextant biopsies from excised prostates. Two other workgroups also using real-time methylation-specific PCR reported that hypermethylation at the EDNRB gene locus encoding the endothelin receptor type B correlates with prostate cancer disease severity (Gleason score and pathologic stage; refs. 28, 43). This implies that EDNRB is a candidate for consideration in a small diagnostic hypermethylation test panel in prostate cancer.

In spite of the fact that we used a unique set of primers for GSTP1, APC, and PTGS2, our hypermethylation results are similar to recent data reported by others who used comparable real-time methylation-specific PCR methods to evaluate hypermethylation in BPH and prostate cancer (26, 28, 43, 52, 53). This suggests that hypermethylation at these genes is widespread and present at different CpG islands in the gene promoter region. In contrast, hypermethylation at RASSF1a and MDR1 gene loci seems more fickle, and recent reports by others (26, 40, 43, 53, 54) who used a similar methylation-specific PCR technology but different primer sets show varying CpG island hypermethylation in prostate cancer and BPH, which differs from our results. This underlines the fact that RASSF1a and MDR1 are not reliable in identifying cancerous prostatic tissue.

CpG island hypermethylation at a single gene locus revealed no correlation with established clinicopathologic variables (i.e., preoperative PSA level, Gleason score, pathologic stage, seminal vesicle or lymph node involvement, surgical margin status, age, etc.; refs. 48, 49). On the other hand, by using the {chi}2 and Fisher's exact test, we were able to show that important prognostic indicators, such as the pathologic stage, extraprostatic extension, and the Gleason score, correlated with the combined hypermethylation results at GSTP1/APC, GSTP1/PTGS2, and GSTP1/APC/PTGS2 (see Table 5). To our knowledge, no such gene combination studies with similar results have been reported. We conclude that a small test panel that quantitatively evaluates hypermethylation at GSTP1, APC, and PTGS2 (possibly including MDR1, RASSF1a, and EDNRB) may suffice to diagnose and prognosticate prostate cancer. However, this hypothesis must be further tested in clinical specimens from a much larger cohort of consecutive patients.


   Acknowledgments
 
We thank Doris Schmidt for excellent technical assistance and Srinivasan Yegnasubramanian for valuable help with statistical analyses.


   Footnotes
 
Grant support: Wissenschaftsfoerderung der Nordrhein Westfälischen Gesellschaft für Urologie, Siegen, Germany (North Rhine-Westphalian section of the German Urological Association; to P.J. Bastian) and Deutsche Krebshilfe (10-1877-We 2; to N. Wernert).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: P.J. Bastian and J. Ellinger contributed equally to this work.

3 Unpublished data. Back

Received 9/ 8/04; revised 1/ 7/05; accepted 2/ 1/05.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Lerner SE, Seay TM, Blute ML, et al. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol 1996;155:821–6.[CrossRef][Medline]
  2. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212–8.[CrossRef][Medline]
  3. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439–43.[Medline]
  4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.[Abstract/Free Full Text]
  5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239–46.[Abstract/Free Full Text]
  6. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29.[Abstract/Free Full Text]
  7. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globoscan 200. Int J Cancer 2001;94:153–6.[CrossRef][Medline]
  8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366–81.[Free Full Text]
  9. de la Taille A, Antiphon P, Salomon L, et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003;61:1181–6.[CrossRef][Medline]
  10. Makhlouf AA, Krupski TL, Kunkle D, Theodorescu D. The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. BJU Int 2004;93:271–4.[CrossRef][Medline]
  11. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursors and pathobiology. Urology 2003;62:55–62.
  12. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol 2004;121:99–107.[CrossRef][Medline]
  13. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 {alpha}-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57:134–9.[CrossRef][Medline]
  14. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001;58:619–24.[CrossRef][Medline]
  15. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769–75.[Abstract/Free Full Text]
  16. Zhou M, Aydin H, Kanane H, Epstein JI. How often does {alpha}-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 2004;8:239–43.
  17. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955–64.[CrossRef][Medline]
  18. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943–53.[Abstract/Free Full Text]
  19. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415–28.[Medline]
  20. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the {pi}-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994;91:11733–7.[Abstract/Free Full Text]
  21. Goessl C, Muller M, Miller K. Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis 2000;3:S17.[CrossRef][Medline]
  22. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004;91:459–77.[CrossRef][Medline]
  23. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225–9.[Abstract/Free Full Text]
  24. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514–9.[Abstract/Free Full Text]
  25. Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003;106:382–7.[CrossRef][Medline]
  26. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004;202:233–40.[CrossRef][Medline]
  27. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425–34.[CrossRef][Medline]
  28. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975–86.[Abstract/Free Full Text]
  29. Li LC, Zhao H, Shiina H, Kane CJ, Dahiya R. PGDB: a curated and integrated database of genes related to prostate cancer. Nucleic Acids Res 2003;31:291–3.[Abstract/Free Full Text]
  30. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617–23.[Abstract/Free Full Text]
  31. Kantharidis P, El-Osta A, de Silva M, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997;3:2025–32.[Medline]
  32. Mahadovan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004;104:1940–51.[Abstract/Free Full Text]
  33. Nagase H, Nakamura Y. Mutations of the PAC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425–34.
  34. Siegsmund MJ, Kreukler C, Steidler A, et al. Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol Res 1997;25:35–41.[CrossRef][Medline]
  35. Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000;6:4618–27.[Abstract/Free Full Text]
  36. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1a in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691–9.[Abstract/Free Full Text]
  37. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315–9.[CrossRef][Medline]
  38. Dammann R, Schagdarsurengin U, Liu L, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003;22:3806–12.[CrossRef][Medline]
  39. Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003;18:665–77.[Medline]
  40. Florl AR, Steinhoff C, Müller M, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004;91:985–94.[CrossRef][Medline]
  41. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002;21:6835–40.[CrossRef][Medline]
  42. Song MS, Song SJ, Ayad NG, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004;6:129–37.[CrossRef][Medline]
  43. Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 2004;205:181–8.[CrossRef][Medline]
  44. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001;29:E65–70.
  45. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410–8.[Abstract/Free Full Text]
  46. Lehmann U, Langer F, Feist H, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605–12.[Abstract/Free Full Text]
  47. Li R, Younes M, Frolov A, et al. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res 2003;23:3413–8.[Medline]
  48. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.[Abstract/Free Full Text]
  49. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445–51.[Abstract]
  50. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131–5.[CrossRef][Medline]
  51. Kawai K, Sakurai M, Sakai T, et al. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 2000;150:147–53.[CrossRef][Medline]
  52. Tokumaru Y, Harden SV, Sun DI, et al. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004;10:5518–22.[Abstract/Free Full Text]
  53. Woodson K, Gillespie J, Hanson J, et al. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate 2004;60:25–31.[CrossRef][Medline]
  54. Enokida H, Shiina H, Igawa M, et al. CpG Hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004;64:5956–62.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
T M Murphy, A S Perry, and M Lawler
The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer
Endocr. Relat. Cancer, March 1, 2008; 15(1): 11 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Henrique, F. R. Ribeiro, D. Fonseca, M. O. Hoque, A. L. Carvalho, V. L. Costa, M. Pinto, J. Oliveira, M. R. Teixeira, D. Sidransky, et al.
High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients
Clin. Cancer Res., October 15, 2007; 13(20): 6122 - 6129.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Valinluck and L. C. Sowers
Inflammation-Mediated Cytosine Damage: A Mechanistic Link between Inflammation and the Epigenetic Alterations in Human Cancers
Cancer Res., June 15, 2007; 67(12): 5583 - 5586.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kawamoto, S. T. Okino, R. F. Place, S. Urakami, H. Hirata, N. Kikuno, T. Kawakami, Y. Tanaka, D. Pookot, Z. Chen, et al.
Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer
Clin. Cancer Res., May 1, 2007; 13(9): 2541 - 2548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. S. Zorn, K. J. Wojno, M. T. McCabe, R. Kuefer, J. E. Gschwend, and M. L. Day
5-Aza-2'-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2136 - 2143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Roupret, V. Hupertan, D. R. Yates, J. W.F. Catto, I. Rehman, M. Meuth, S. Ricci, R. Lacave, G. Cancel-Tassin, A. de la Taille, et al.
Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage
Clin. Cancer Res., March 15, 2007; 13(6): 1720 - 1725.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Widschwendter and U. Menon
Circulating Methylated DNA: A New Generation of Tumor Markers
Clin. Cancer Res., December 15, 2006; 12(24): 7205 - 7208.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. S Perry, R. Foley, K. Woodson, and M. Lawler
The emerging roles of DNA methylation in the clinical management of prostate cancer.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. N. Poynter, K. A. Cooney, J. D. Bonner, K. A. White, L. P. Tomsho, G. Rennert, and S. B. Gruber
APC I1307K and the Risk of Prostate Cancer.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 468 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Guan, X. Zhou, N. Soulitzis, D. A. Spandidos, and N. C. Popescu
Aberrant Methylation and Deacetylation of Deleted in Liver Cancer-1 Gene in Prostate Cancer: Potential Clinical Applications
Clin. Cancer Res., March 1, 2006; 12(5): 1412 - 1419.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. K. Vanaja, K. V. Ballman, B. W. Morlan, J. C. Cheville, R. M. Neumann, M. M. Lieber, D. J. Tindall, and C. Y.F. Young
PDLIM4 Repression by Hypermethylation as a Potential Biomarker for Prostate Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1128 - 1136.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bastian, P. J.
Right arrow Articles by von Ruecker, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bastian, P. J.
Right arrow Articles by von Ruecker, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention